Inflammatory condition of skin

This section encompasses a wide range of skin conditions, comprising a number of separate aetiologies. They fall into this category due to their common inflammatory pathology,

...


Read more on Inflammatory condition of skin

 

 

Latest news articles

Added 6 days ago Drug news

Leo Pharma A/S acquires rights to develop and market Kyntheum for moderate-to-severe psoriasis outside of Europe

Leo Pharma A/S, a global leader in medical dermatology, has announced it has acquired the exclusive rights to develop and...

Added 9 days ago Drug news

Phase IV IXORA-R study of Taltz meets primary endpoint in plaque psoriasis

Eli Lilly announced Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase...

Added 10 days ago Drug news

Phase III ECLIPSE study of Tremfya showed superior long-term efficacy in psoriasis

Results from the Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya (guselkumab), from J&J Janssen Cilag, compared...

Search all news articles for Inflammatory condition of skin
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Load more

Guidelines

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light–based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents...

Added 11 days ago

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process.

Added 1 year ago

British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018

The overall objective of the guidelines is to provide up-todate, evidence-based recommendations on the investigation and management of secondary pruritus without underlying skin disorder and generalized pruritus of unknown origin (GPUO) in adults...

Added 1 year ago

Search all guidelines for Inflammatory condition of skin
 

Journal articles

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.

Objective: To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial.

Added 2 months ago

Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.

T helper 17 (TH17) cells and interleukin-17A (IL-17A) produced by them are critical in autoinflammatory diseases, such as psoriasis. IL-17A has been shown to signal through IL-17 receptor A/IL-17 receptor C (IL-17RA/IL-17RC)...

Added 2 months ago

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.

Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors.

Added 3 months ago

Search all journal articles for Inflammatory condition of skin
 

Clinical trials

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.

Added 5 months ago

A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Added 5 months ago

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Added 5 months ago

Search all clinical trials for Inflammatory condition of skin
 
Lisa Lishman

EULAR 2018 – Biosimilars: the future of rheumatology?

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?

CME

Psoriasis: diagnosis and individualised therapy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
15

Ask an expert: Psoriasis

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Psoriasis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Inflammatory condition of skin